Phase I, first-in-man, randomised, placebo-controlled, single dose escalation study to investigate the effects of LPH-5 on safety, tolerability, pharmacokinetic and pharmacodynamic parameters in healthy participants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512330-15-00

Acronym

LPH-5CS01

Enrollment

Registered

2024-09-13

Start date

2025-08-05

Completion date

2025-12-23

Last updated

2025-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026